Entera Bio Ltd.

ENTX

Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
SEC CIK: 0001638097

SEC filings (opens in a new tab)

No open-market purchases or sales by Entera Bio Ltd. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $19.0M in total; no superinvestor holds it.

Q1 2023 vs. Q4 2022

How the institutions holding Entera Bio Ltd. changed between Q4 2022 and Q1 2023.

All holders in Q1 2023 All holders in Q4 2022

13F holders of ENTX: Q4 2022 compared with Q1 2023
Measure	Q4 2022	Q1 2023	Change
Holders	12	9	−3
Shares	3.05M	2.83M	−220.2K (−7.2%)
Value	$415.9K	$3.28M	+$2.87M (+689.8%)

New holders (1)

Institutions that held Entera Bio Ltd. at the end of Q1 2023 but not at the end of Q4 2022.

Institutions new to ENTX in Q1 2023
Institution	Shares	Value	% of portfolio
JPMorgan Chase & Co	1,868	$2.00K	0.00%

Sold out (4)

Institutions that held Entera Bio Ltd. at the end of Q4 2022 and filed for Q1 2023 without it.

Institutions that sold out of ENTX in Q1 2023
Institution	Shares, Q4 2022	Value, Q4 2022
Millennium Management LLC	46,000	$34.0K
Citadel Advisors LLC	30,465	$22.2K
HRT Financial LP	15,236	$11.0K
BlackRock Inc.	500	$365